Christopher Raymond
Stock Analyst at Raymond James
(3.39)
# 1,007
Out of 5,124 analysts
139
Total ratings
53.51%
Success rate
2.05%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $9.93 | +151.76% | 1 | Dec 18, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $9 → $10 | $5.83 | +71.53% | 10 | Nov 4, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $5.50 | +136.36% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $7.95 | +264.78% | 2 | Oct 21, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $231 → $284 | $228.49 | +24.29% | 13 | Oct 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $134.86 | -48.09% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $175.99 | -34.66% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.13 | +696.46% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $59.43 | +112.01% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $3.32 | +20.48% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $453.36 | +17.57% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $771.87 | +31.24% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $23.00 | +508.70% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $65.30 | +10.26% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $3.01 | +331.89% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $7.36 | +919.02% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $11.29 | +573.16% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.61 | +1,542.31% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $26.29 | +25.52% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $35.52 | -38.06% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.61 | +148.45% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $327.31 | -12.01% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $27.22 | +50.62% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $46.48 | -39.76% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $100.59 | -60.23% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.64 | +1,495.74% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.74 | +5,417.24% | 2 | Mar 13, 2020 |
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $9.93
Upside: +151.76%
Ardelyx
Nov 4, 2025
Maintains: Neutral
Price Target: $9 → $10
Current: $5.83
Upside: +71.53%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $5.50
Upside: +136.36%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $7.95
Upside: +264.78%
AbbVie
Oct 10, 2025
Maintains: Overweight
Price Target: $231 → $284
Current: $228.49
Upside: +24.29%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $134.86
Upside: -48.09%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $175.99
Upside: -34.66%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.13
Upside: +696.46%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $59.43
Upside: +112.01%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $3.32
Upside: +20.48%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $453.36
Upside: +17.57%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $771.87
Upside: +31.24%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $23.00
Upside: +508.70%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $65.30
Upside: +10.26%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $3.01
Upside: +331.89%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $7.36
Upside: +919.02%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $11.29
Upside: +573.16%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.61
Upside: +1,542.31%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $26.29
Upside: +25.52%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $35.52
Upside: -38.06%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.61
Upside: +148.45%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $327.31
Upside: -12.01%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $27.22
Upside: +50.62%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $46.48
Upside: -39.76%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $100.59
Upside: -60.23%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.64
Upside: +1,495.74%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.74
Upside: +5,417.24%